Drug Type Unknown |
Synonyms- |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Blindness | Phase 2 | US | 04 Aug 2021 | |
Retinal Degeneration | Phase 2 | US | 04 Aug 2021 |
Phase 1/2 | - | Optogenetics | xijiratrym(zgwoxkxuam) = liafahtofe ankshgkynq (aashneccsj ) | - | 01 Jun 2020 | ||
Optogenetics | xijiratrym(zgwoxkxuam) = urloifbwyn ankshgkynq (aashneccsj ) | ||||||
Phase 1/2 | - | - | oywxnptqee(bqbbyhwdxr) = The most common adverse events (AEs) were mild anterior chamber inflammation responsive to corticosteroid treatment rlkqhqaqhs (ayzeecbyvi ) View more | Positive | 28 Apr 2020 | ||